Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer’s 38th Annual Meeting
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that an abstract involving SNAP-CAR has been accepted for presentation at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023). SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego.
The poster presentation titled, “SNAP CAR T cells for programmable antigen targeting,” will detail research involving SNAP-CAR, a “universal” CAR T cell therapy platform that can be adapted to different cancer indications. Licensed by Coeptis from the University of Pittsburgh, SNAP-CAR offers an opportunity to direct the power of CAR T to an array of cancers that have, until now, been inaccessible via current cell therapy technologies by providing a highly programmable antigen targeting platform.
“Having research on SNAP-CAR presented at such a renowned oncology conference as SITC provides additional validation of the technology’s potential and the exceptional work being conducted by Dr. Lohmueller and his team at the University of Pittsburgh,” said Dave Mehalick, President and CEO of Coeptis Therapeutics. “SNAP-CAR represents a powerful technology with the potential to be engineered to address numerous cancers, including HER2-expressing cancer, which we are targeting as our potential first-in-human clinical development program.”